Targeting DNA damage repair precision medicine strategies in cancer
Curr Opin Pharmacol. 2023 May 4;70:102381. doi: 10.1016/j.coph.2023.102381. Online ahead of print.ABSTRACTDNA repair targeted therapeutics is a promising precision medicine strategy in cancer. The development and clinical use of PARP inhibitors has transformed lives for many patients with BRCA germline deficient breast and ovarian cancer as well as platinum sensitive epithelial ovarian cancers. However, lessons learnt from the clinical use of PARP inhibitors also confirm that not all patients respond either due to intrinsic or acquired resistance. Therefore, the search for additional synthetic lethality approaches is an ac...
Source: Current Opinion in Pharmacology - May 6, 2023 Category: Drugs & Pharmacology Authors: Juliette Brownlie Sanat Kulkarni Mashael Algethami Jennie N Jeyapalan Nigel P Mongan Emad A Rakha Srinivasan Madhusudan Source Type: research
Targeting DNA damage repair precision medicine strategies in cancer
Curr Opin Pharmacol. 2023 May 4;70:102381. doi: 10.1016/j.coph.2023.102381. Online ahead of print.ABSTRACTDNA repair targeted therapeutics is a promising precision medicine strategy in cancer. The development and clinical use of PARP inhibitors has transformed lives for many patients with BRCA germline deficient breast and ovarian cancer as well as platinum sensitive epithelial ovarian cancers. However, lessons learnt from the clinical use of PARP inhibitors also confirm that not all patients respond either due to intrinsic or acquired resistance. Therefore, the search for additional synthetic lethality approaches is an ac...
Source: Current Opinion in Pharmacology - May 6, 2023 Category: Drugs & Pharmacology Authors: Juliette Brownlie Sanat Kulkarni Mashael Algethami Jennie N Jeyapalan Nigel P Mongan Emad A Rakha Srinivasan Madhusudan Source Type: research
Purinergic signaling pathway in severe COVID-19
Curr Opin Pharmacol. 2023 Mar 23;70:102379. doi: 10.1016/j.coph.2023.102379. Online ahead of print.ABSTRACTSubstantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation ...
Source: Current Opinion in Pharmacology - April 23, 2023 Category: Drugs & Pharmacology Authors: Lourdes Arruvito In és Sananez Vanesa Seery Constanza Russo Jorge Geffner Source Type: research
Purinergic signaling pathway in severe COVID-19
Curr Opin Pharmacol. 2023 Mar 23;70:102379. doi: 10.1016/j.coph.2023.102379. Online ahead of print.ABSTRACTSubstantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation ...
Source: Current Opinion in Pharmacology - April 23, 2023 Category: Drugs & Pharmacology Authors: Lourdes Arruvito In és Sananez Vanesa Seery Constanza Russo Jorge Geffner Source Type: research
Purinergic signaling pathway in severe COVID-19
Curr Opin Pharmacol. 2023 Mar 23;70:102379. doi: 10.1016/j.coph.2023.102379. Online ahead of print.ABSTRACTSubstantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation ...
Source: Current Opinion in Pharmacology - April 23, 2023 Category: Drugs & Pharmacology Authors: Lourdes Arruvito In és Sananez Vanesa Seery Constanza Russo Jorge Geffner Source Type: research
Purinergic signaling pathway in severe COVID-19
Curr Opin Pharmacol. 2023 Mar 23;70:102379. doi: 10.1016/j.coph.2023.102379. Online ahead of print.ABSTRACTSubstantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation ...
Source: Current Opinion in Pharmacology - April 23, 2023 Category: Drugs & Pharmacology Authors: Lourdes Arruvito In és Sananez Vanesa Seery Constanza Russo Jorge Geffner Source Type: research
Purinergic signaling pathway in severe COVID-19
Curr Opin Pharmacol. 2023 Mar 23;70:102379. doi: 10.1016/j.coph.2023.102379. Online ahead of print.ABSTRACTSubstantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation ...
Source: Current Opinion in Pharmacology - April 23, 2023 Category: Drugs & Pharmacology Authors: Lourdes Arruvito In és Sananez Vanesa Seery Constanza Russo Jorge Geffner Source Type: research
Purinergic signaling pathway in severe COVID-19
Curr Opin Pharmacol. 2023 Mar 23;70:102379. doi: 10.1016/j.coph.2023.102379. Online ahead of print.ABSTRACTSubstantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation ...
Source: Current Opinion in Pharmacology - April 23, 2023 Category: Drugs & Pharmacology Authors: Lourdes Arruvito In és Sananez Vanesa Seery Constanza Russo Jorge Geffner Source Type: research
Purinergic signaling pathway in severe COVID-19
Curr Opin Pharmacol. 2023 Mar 23;70:102379. doi: 10.1016/j.coph.2023.102379. Online ahead of print.ABSTRACTSubstantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation ...
Source: Current Opinion in Pharmacology - April 23, 2023 Category: Drugs & Pharmacology Authors: Lourdes Arruvito In és Sananez Vanesa Seery Constanza Russo Jorge Geffner Source Type: research
Purinergic signaling pathway in severe COVID-19
Curr Opin Pharmacol. 2023 Mar 23;70:102379. doi: 10.1016/j.coph.2023.102379. Online ahead of print.ABSTRACTSubstantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation ...
Source: Current Opinion in Pharmacology - April 23, 2023 Category: Drugs & Pharmacology Authors: Lourdes Arruvito In és Sananez Vanesa Seery Constanza Russo Jorge Geffner Source Type: research
Purinergic signaling pathway in severe COVID-19
Curr Opin Pharmacol. 2023 Mar 23;70:102379. doi: 10.1016/j.coph.2023.102379. Online ahead of print.ABSTRACTSubstantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation ...
Source: Current Opinion in Pharmacology - April 23, 2023 Category: Drugs & Pharmacology Authors: Lourdes Arruvito In és Sananez Vanesa Seery Constanza Russo Jorge Geffner Source Type: research
Extracellular adenosine signaling in bone health and disease
Curr Opin Pharmacol. 2023 Apr 10;70:102378. doi: 10.1016/j.coph.2023.102378. Online ahead of print.ABSTRACTPurinergic signaling is a key molecular pathway in the maintenance of bone health and regeneration. P1 receptor signaling, which is activated by extracellular adenosine, has emerged as a key metabolic pathway that regulates bone tissue formation, function, and homeostasis. Extracellular adenosine is mainly produced by ectonucleotidases, and alterations in the function of these enzymes or compromised adenosine generation can result in bone disorders, such as osteoporosis and impaired fracture healing. This mini review ...
Source: Current Opinion in Pharmacology - April 12, 2023 Category: Drugs & Pharmacology Authors: Hunter Newman Shyni Varghese Source Type: research
Extracellular adenosine signaling in bone health and disease
Curr Opin Pharmacol. 2023 Apr 10;70:102378. doi: 10.1016/j.coph.2023.102378. Online ahead of print.ABSTRACTPurinergic signaling is a key molecular pathway in the maintenance of bone health and regeneration. P1 receptor signaling, which is activated by extracellular adenosine, has emerged as a key metabolic pathway that regulates bone tissue formation, function, and homeostasis. Extracellular adenosine is mainly produced by ectonucleotidases, and alterations in the function of these enzymes or compromised adenosine generation can result in bone disorders, such as osteoporosis and impaired fracture healing. This mini review ...
Source: Current Opinion in Pharmacology - April 12, 2023 Category: Drugs & Pharmacology Authors: Hunter Newman Shyni Varghese Source Type: research
Extracellular adenosine signaling in bone health and disease
Curr Opin Pharmacol. 2023 Apr 10;70:102378. doi: 10.1016/j.coph.2023.102378. Online ahead of print.ABSTRACTPurinergic signaling is a key molecular pathway in the maintenance of bone health and regeneration. P1 receptor signaling, which is activated by extracellular adenosine, has emerged as a key metabolic pathway that regulates bone tissue formation, function, and homeostasis. Extracellular adenosine is mainly produced by ectonucleotidases, and alterations in the function of these enzymes or compromised adenosine generation can result in bone disorders, such as osteoporosis and impaired fracture healing. This mini review ...
Source: Current Opinion in Pharmacology - April 12, 2023 Category: Drugs & Pharmacology Authors: Hunter Newman Shyni Varghese Source Type: research
Extracellular adenosine signaling in bone health and disease
Curr Opin Pharmacol. 2023 Apr 10;70:102378. doi: 10.1016/j.coph.2023.102378. Online ahead of print.ABSTRACTPurinergic signaling is a key molecular pathway in the maintenance of bone health and regeneration. P1 receptor signaling, which is activated by extracellular adenosine, has emerged as a key metabolic pathway that regulates bone tissue formation, function, and homeostasis. Extracellular adenosine is mainly produced by ectonucleotidases, and alterations in the function of these enzymes or compromised adenosine generation can result in bone disorders, such as osteoporosis and impaired fracture healing. This mini review ...
Source: Current Opinion in Pharmacology - April 12, 2023 Category: Drugs & Pharmacology Authors: Hunter Newman Shyni Varghese Source Type: research
